Outsourcing Pharma

APRIL 11, 2023

OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction compliance is headed and how they would convert risk-based approaches into a confidence-based assurances. (..)

Compliance 52

Compliance Life Science Regulation Marketing 52

FDA Law Blog

SEPTEMBER 26, 2023

(HP&M), a leader in providing legal and regulatory support to the life sciences industries, today announced the appointment of Jeff Grizzel to the newly created position of Chief Marketing Officer (CMO). Jeff joins HP&M from Compliance Architects where he served as Vice President of Business Development.

Marketing 59

Marketing Life Science Compliance Business Development 59

FDA Law Blog

NOVEMBER 6, 2023

is pleased to announce it took top honors in two categories in the 2023 LMG Life Sciences Awards, which recognize the best life science practitioners and firms over the past 12 months from the United States, Canada, and Europe. life sciences industry. WASHINGTON, DC — Hyman, Phelps & McNamara, P.C.

Life Science 40

Life Science Cosmetics Regulation Drugs 40

XTalks

JANUARY 9, 2024

Swoop , a leader in healthcare marketing, recently introduced a groundbreaking portfolio of predictive AI targeting for pharmaceutical and life sciences advertisers. This capability will usher in a new era in healthcare marketing, moving beyond traditional methods that rely on past data to a future-focused approach.

Marketing 104

Marketing Life Science Compliance Doctors 104

XTalks

JULY 5, 2022

Employee retention and motivation is a challenge that all life science companies face. A corporate compliance training program is a part of many onboarding programs to ensure employees are up to date with the latest rules and regulations they must adhere to while working for the company.

Life Science 52

Life Science Compliance Packaging Packaging 52

Advarra

SEPTEMBER 14, 2023

In the clinical research space, GxP is a set of quality regulations and guidelines designed to establish the safety, efficacy, and integrity of pharmaceuticals, medical devices, and clinical trials. This blog explores key concepts, regulations, and the importance of GxP in delivering successful clinical trials.

Clinical Research 52

Clinical Research Compliance Research Regulation 52

Pharma in Brief

MAY 4, 2023

The Ontario Superior Court ( ONSC ) has dismissed a claim for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations ) brought by Apotex Inc. The Court conducted a purposive interpretation of the Regulations and found that Apotex did not meet the statutory requirements for damages.

Regulation 52

Regulation Sales Production Compliance 52

Pharma in Brief

SEPTEMBER 8, 2022

On August 17, 2022, the Federal Court dismissed applications for judicial review regarding the product-specificity requirements for addressing patents listed on the Patent Register under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). Background. Sections 4 and 5 work together.

Marketing 52

Marketing Drugs Regulation Compliance 52

FDA Law Blog

MARCH 6, 2024

Claud will be featured at the Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products in New York, NY. Prior to HP&M, John served 15 years at the Department of Justice, serving most recently as the Assistant Director of the Consumer Protection Branch, where he led the Corporate Compliance and Policy Unit.

Cosmetics 59

Cosmetics Compliance Generic Drugs Regulation 59

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. The challenge is harnessing the power of AI within a highly regulated industry. The key challenge for all regulators next year is ensuring that they can keep up with the progress of the technology.”

Genome 139

Genome Genomics Life Science Gene Therapy 139

Pharma in Brief

JULY 25, 2022

The Guide provides a detailed review of the key regimes, including: Data protection market exclusivity; The Patented Medicines (Notice of Compliance) Regulations (PMNOC), linking generic market access to patent rights; Certificate of Supplementary Protection (CSP) exclusivity; Biologics; and.

Life Science 52

Life Science Compliance Regulation Marketing 52

Pharma in Brief

NOVEMBER 16, 2020

On October 29, 2020, the Federal Court ordered the Minister of Health to immediately issue a notice of compliance ( NOC ) for a biosimilar drug following a dispute about the effective date of a consent letter under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). Background.

Regulation 52

Regulation Compliance Marketing Licensing 52

Pharma in Brief

JANUARY 17, 2024

The Federal Court of Appeal ( FCA ) held that it is abuse of process for a generic or biosimilar manufacturer to split its case across multiple notices of allegation ( NOAs ) under the Patented Medicines (Notice of Compliance) Regulations ( Regulations ). Background Janssen markets INVEGA SUSTENNA® (paliperidone palmitate).

Regulation 52

Regulation Compliance Manufacturing Production 52

Pharmaceutical Technology

OCTOBER 28, 2022

Designed to explain either the risk management plan (RMP) or clinical trial results (CTR) in a way that a child can understand, lay summaries are now a required document for all clinical trials in the European Union (EU) following changes to EU Clinical Trials Regulations (EU-CTR) regulations earlier this year.

Clinical Trials 130

Clinical Trials Clinical Trials Life Science Trials 130

Pharma in Brief

AUGUST 24, 2022

Importantly, the ONCA decision reaffirms that innovators are not liable beyond damages available under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations ) for the legitimate exercise of their rights under the Patent Act and the Regulations. Background. Eli Lilly Canada Inc.

Regulation 52

Regulation Compliance Life Science Sales 52

Pharma in Brief

MARCH 9, 2021

The Federal Court of Appeal has affirmed one of the last judgments granting a prohibition order under subsection 6(1) of the pre-September 2017 Patented Medicines (Notice of Compliance) Regulations (the PM(NOC) Regulations ). ZYTIGA® (abiraterone acetate or AA ) is a drug marketed in Canada by Janssen Inc., Background.

Regulation 52

Regulation Compliance Production Life Science 52

Pharma in Brief

JANUARY 7, 2024

Whether Florida is able to import drugs from Canada, including in light of Canadian regulations controlling drug exports, remains to be seen. Eligible drugs must: (i) be approved by Health Canada; and (ii) meet FDA-approval conditions for a drug currently marketed in the US (aside from US labeling). 01.014.8).

Drugs 52

Drugs Regulation FDA Approval Manufacturing 52

Pharma in Brief

JANUARY 26, 2022

The Federal Court has confirmed that issues of infringement, including by inducement, may be decided by summary trial in an infringement action under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). collectively, the Plaintiffs ). the PMS Product ). In that case, Manson J.

Regulation 52

Regulation Trials Production Compliance 52

Drug Channels

MARCH 6, 2023

Experts from across the industry will discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Plus, assess how companies are internally planning for these changes.

Drugs 83

Drugs Life Science Compliance Branding 83

XTalks

JANUARY 29, 2024

Don’t forget to explore the Xtalks Job Search platform to embark on your journey to landing your dream job in the life sciences industry today. Related: Life Science Consulting Jobs: A Unique Career What Does a Healthcare Consultant Do?

Life Science 105

Life Science Regulation Marketing Compliance 105

ACRP blog

APRIL 5, 2023

The life sciences sector is increasingly leveraging technology across its operations, and this trend will continue in 2023 with more collaborations and partnerships between pharmaceutical, biotechnology, and medical device companies and information technology vendors, Lyons adds.

Big Data 52

Big Data Clinical Trials Clinical Trials Life Science 52

The Pharma Data

NOVEMBER 10, 2020

Crohn’s Disease Therapeutics Market Size $4.7 Weiner, chairman of the scientific advisory board of Tiziana Life Sciences, commented: “We understand that this will be the first-ever study with ‘take-home’ capsules of any mAb for immunotherapies for human diseases. The CD therapeutic market size will be worth $4.7

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

Delveinsight

SEPTEMBER 8, 2021

Especially in the field of Pharmaceutical & Life Sciences, a company’s all-around product life-cycle stages, which consist of planning, designing, constructing, product testing, and commissioning processes are provided by a Pharma Consultant. Market Assessment & Operational Sales. Pharma Consultant.

Marketing 52

Marketing Production Sales Life Science 52

Cloudbyz

APRIL 6, 2023

Cloudbyz offers a range of clinical research management solutions that are integrated with various clinical trials processes, connecting them internally and externally with stakeholders from the life sciences, medical devices, and CRO sectors.

Life Science 52

Life Science Compliance Clinical Research Clinical Trials 52

Pharma in Brief

APRIL 13, 2021

The Food and Drug Regulations ( FDR ) have been amended to allow for continued expedited review of COVID-19 drugs (including vaccines) while transitioning to authorizations by way of a full notice of compliance ( NOC ) under the FDR.

Regulation 52

Regulation Drugs Vaccination Vaccine 52

pharmaphorum

OCTOBER 27, 2022

To help ensure compliance, it is advisable for companies to establish procedures to assess and verify IT security of social media and digital channels, and to review and monitor company activities, content, and materials. Therefore, companies are encouraged to establish a methodology for calculating fair market value rates.

Life Science 95

Life Science Compliance Regulation Cosmetics 95

Pharma in Brief

MAY 29, 2023

The CSP Guidance was revised to reflect amendments to the definition of “authorization for sale” in the Certificate of Supplementary Protection Regulations ( CSP Regulations ) and to reflect changes to Health Canada’s administrative practices. Certificate of Supplementary Protection Regulations , SOR/2017-165

Regulation 59

Regulation Sales Clinical Trials Clinical Trials 59

pharmaphorum

SEPTEMBER 7, 2020

Wokingham, United Kingdom —4 September 2020 — PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Robert Bowdish as Director of Clinical Trials Sales for North America. PRISYM ID makes new senior appointment to drive further growth in clinical trials arena. www.prisymid.com.

Clinical Trials 52

Clinical Trials Clinical Trials Sales Compliance 52

pharmaphorum

FEBRUARY 4, 2021

Adams believes this positive start to the year is a sign that life science and medical device companies are looking for expert partners who understand the operational and regulatory challenges facing them and can deliver scalable solutions that meet their unique requirements. “It The challenge now is to lock in these gains.

Life Science 52

Life Science Clinical Trials Clinical Trials Regulation 52

pharmaphorum

JANUARY 20, 2022

Companies seek efficiency and speed to market during the content creation process, review and approval cycles, and thus the collective time for content to be approved for distribution, says Ian Hale, vice president of commercial content at Veeva Systems. Every country has its regulations. Compliant pharma content.

Compliance 98

Compliance Branding Sales Marketing 98

pharmaphorum

OCTOBER 19, 2022

Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in life sciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the life sciences industry creates content.

Life Science 91

Life Science Compliance Production Pharma Companies 91

Cloudbyz

MARCH 15, 2023

offers a seamless, secure, and efficient cloud platform for capturing, managing, and analyzing clinical trial data, empowering researchers to deliver life-changing treatments faster and smarter. Compliance & Regulation: Full compliance with FDA 21 CFR Part 11, GDPR, HIPAA, and other global regulatory standards.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Pharma Business Blog

FEBRUARY 7, 2023

A proposal has been put forward to amend the transitional provisions for certain medical devices and in vitro diagnostic medical devices (amending Regulations (EU) 2017/745 (MDR) 1 and (EU) 2017/746 (IVDR) 2. Taken together, there is the risk of shortages of medical devices on the EU market.

Regulation 52

Regulation In-Vitro Manufacturing Life Science 52

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 97

Life Science Pharma Companies Sales Marketing 97

XTalks

MAY 17, 2024

The spa can obtain and distribute compounded tirzepatide products on the condition that they are produced in compliance with US federal law. Fellow GLP-1 maker over companies selling compounded versions of its semaglutide products, Ozempic and Wegovy, and using fraudulent marketing. The med spa has agreed to this requirement.

Sales 52

Sales FDA Approval Pharmacy Production 52

Pharma in Brief

FEBRUARY 28, 2024

Background Janssen markets INVEGA SUSTENNA ® (paliperidone palmitate) for the treatment of schizophrenia and related disorders. PMS ) sought a Notice of Compliance to market a generic version of INVEGA SUSTENNA ® (the PMS Product ). Janssen’s Canadian Patent No. 2,655,335 ( 335 Patent ) teaches a dosing regimen.

Compliance 52

Compliance Production Regulation Marketing 52

Pharma in Brief

JANUARY 10, 2024

However, many details remain to be addressed in forthcoming regulations. CIPO consulted on proposed features of the regulations in 2023 (see here ), including many factors that would reduce the length of the PTA term. Draft regulations are expected to be released for consultation in 2024. The Guidance was last updated in 2005.

Regulation 52

Regulation Drugs Production Medicine 52